Arcus Biosciences (RCUS) reported $247M in revenue for fiscal 2025, −4.3% year on year. That ranks #2579 by revenue among 2853 SEC filers and #266 in Healthcare. It posted a net loss of −$353M for the same year. Revenue has grown 90.7% a year on average since 2017 ($1.4M then). The fiscal 2025 balance sheet shows $1.1B in total assets, $222M in cash and $99.0M in long-term debt.
2018–2021 missing from the revenue series. In those years the company tagged only part of its revenue in XBRL: the tag it used is 7.50 times smaller than its total revenue in the latest year. Showing those figures next to the later ones would draw a jump that never happened, so they are left out rather than shown.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $247M | −4.3% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$386M | −$56.0M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$353M | −$70.0M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$482M | −$312M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $2.0M | −66.7% | FY20252025-12-31 |
| Total assetsAssets | $1.1B | −1.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $631M | +30.1% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $222M | +48.0% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $99.0M | +106.3% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $17.0M | −$128M | Open → |
| Q2 20262026-06-30 | $41.0M | −$91.0M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Arcus Biosciences, Inc.
- Ticker
- RCUS
- Exchange
- NYSE
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001724521
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Omada HealthOMDA | $260M | −$12.8M |
| SchrodingerSDGR | $256M | −$103M |
| Lemaitre VascularLMAT | $250M | $57.7M |
| Arcus BiosciencesRCUS | $247M | −$353M |
| Keros TherapeuticsKROS | $244M | $87.0M |
| Staar SurgicalSTAA | $239M | −$80.4M |
| VaxartVXRT | $237M | $16,327 |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Arcus Biosciences — Key figures |url=https://companiesranked.com/en/company/arcus-biosciences |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Arcus Biosciences — Key figures. CompaniesRanked. https://companiesranked.com/en/company/arcus-biosciencesBibTeX
@misc{companiesranked-en-company-arcus-biosciences-2026,
author = {{CompaniesRanked}},
title = {{Arcus Biosciences — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/arcus-biosciences}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001724521-26-000009 · February 25, 2026
{{cite web |title=Arcus Biosciences — Key figures — 10-K (0001724521-26-000009) |url=https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.